Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Equillium, Inc. - Common Stock (NQ:EQ)

0.4952 -0.0578 (-10.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Equillium, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results
 
Via Benzinga
Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients
Equillium's itolizumab showed improved longer-term outcomes in aGVHD despite missing primary endpoints. FDA feedback on potential Accelerated Approval is expected in May. 
Via Benzinga
Top movers in Thursday's pre-market session
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
From Equillium, Inc.
Via Business Wire
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
From Equillium, Inc.
Via Business Wire
Which stocks are moving on Thursday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
From Equillium, Inc.
Via Business Wire
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
From Equillium, Inc.
Via Business Wire
Equillium to Present at the Stifel Healthcare Conference
From Equillium, Inc.
Via Business Wire
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
From Equillium Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Equillium Maintains Rights to Itolizumab Following Ono Partnership
From Equillium Inc.
Via Business Wire
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
From Equillium, Inc.
Via Business Wire
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
From Equillium, Inc.
Via Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
From Equillium, Inc.
Via Business Wire
EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q2 2024
EQ stock results show that Equillium beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights
From Equillium Inc.
Via Business Wire
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
From Equillium, Inc.
Via Business Wire
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
From Equillium, Inc.
Via Business Wire
Equillium to Participate in Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
Equillium to be included in the Russell Microcap® Index
From Equillium, Inc.
Via Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire
Dow Surges 200 Points; Designer Brands Shares Plunge Following Q1 Earnings
 
Via Benzinga
Topics Stocks
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data
Equillium released topline data from its Phase 2 study of EQ101 in adult patients with alopecia areata, a disease that results in patchy hair loss. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.